It is clear that depression leads to significant morbidity and mortality. Depression is a leading
cause of global health-related burdens. Although there are effective treatments (described in …

BACKGROUND: We evaluated the comparative efficacy and safety of venlafaxine extended
release (ER) and fluoxetine in the acute and continuation phases of treatment. METHODS …

BACKGROUND: Psychosocial outcomes from the Prevention of Recurrent Episodes of
Depression with Venlafaxine ER for Two Years (PREVENT) study were evaluated …

Background Residual symptoms are detrimental to prognosis in major depressive disorder
(MDD); however, little is known about the contribution of each residual symptom in …

Objective: Almost two-thirds of patients with major depressive disorder do not achieve
remission with initial treatments. Thus, identifying and providing effective, feasible, and safe …

During a multisite, NIMH-sponsored clinical trial entitled,“Research Evaluating the Value of
Augmentation of Medication by Psychotherapy”(REVAMP), we assessed the adequacy of …

Objectives: To compare the efficacy and safety of desvenlafaxine (administered as
desvenlafaxine succinate) with placebo in reducing relapse rate in patients with major …

The probability of achieving and sustaining symptomatic remission in major depressive
disorder (MDD) with first-line pharmacotherapy is approximately 30%. Ample documentation …

Importance More than 50% of older adults with late-life major depressive disorder fail to
respond to initial treatment with first-line pharmacological therapy. Objectives To assess …

Objective: To evaluate the effects of sex and menopausal status on acute-, continuation-,
and maintenance-phase treatment outcomes in patients with recurrent major depressive …